-
公开(公告)号：EP1857459A3
公开(公告)日：2007-11-28
申请号：EP07015684.9
申请日：2004-01-23
IPC分类号： C07D487/04 , C07D519/00 , A61K31/519 , A61P1/00 , A61P25/00 , C07D239/00 , C07D231/00 , C07D491/00 , C07D487/00
CPC分类号： C07D487/04
摘要： The present invention provides a pyrazolopyrimidine compound of the formula [I]:
wherein R 1 is
(A) a substituted aryl group,
(B) an optionally substituted nitrogen-containing aliphatic heteromonocyclic group,
(C) a substituted cyclo-lower alkyl group,
(D) an optionally substituted amino group, or
(E) a substituted heteroaryl group,
R 2 is (a) an optionally substituted heteroaryl group or (b) an optionally substituted aryl group,
Y is a single bond, a lower alkylene group or a lower alkenylene group,
Z is a group of the formula: -CO-, -CH 2 -, -SO 2 or a group of the formula:
Q is a lower alkylene group, and q is an integer of 0 or 1 or a pharmaceutically acceptable salt thereof, which has a small conductance potassium channel (SK channel) blocking activity and is useful as a medicament and a process for preparing the same.-
公开(公告)号：EP1789389A1
公开(公告)日：2007-05-30
申请号：EP05785646.0
申请日：2005-09-16
发明人： MIYAKE, Tsutomu, c/o TANABE SEIYAKU Co, Ltd, , YAMANAKA, Takeshi c/o TANABE SEIYAKU Co, Ltd, , KINO, Rie c/o TANABE SEIYAKU Co, Ltd, , ASAI, Hidetoshi c/o TANABE SEIYAKU Co, Ltd,
IPC分类号： C07D211/58 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/497 , A61K31/5377 , A61K31/541 , A61P43/00 , C07D401/04 , C07D401/06 , A61K31/4468 , C07D405/04 , C07D405/06 , C07D409/04 , C07D409/06
CPC分类号： C07D211/58 , C07D211/62 , C07D211/78 , C07D211/96 , C07D257/04 , C07D401/04 , C07D401/06 , C07D401/14 , C07D405/04 , C07D405/06 , C07D405/14 , C07D409/04 , C07D409/06
摘要： The present invention is to provide a piperidine compound represented by the formula [I]: wherein Ring A is an optionally substituted benzene ring, Ring B is an optionally substituted benzene ring, R1 is hydrogen atom or a substituent for amino group, R2 is hydrogen atom, an optionally substituted hydroxyl group, an optionally substituted amino group, an optionally substituted alkyl group, a substituted carbonyl group or a halogen atom, Z is oxygen atom or -N(R3)-, R3 is hydrogen atom or an optionally substituted alkyl group, R4a and R4b may be the same or different, and each is hydrogen atom or an optionally substituted alkyl group, or a pharmaceutically acceptable salt thereof, which has an excellent tachykinin receptor antagonistic action.
-
3.发明公开METHOD OF PRODUCING VASCULAR ENDOTHELIAL CELLS FROM PRIMATE EMBRYONIC STEM CELLS 审中-公开用于生产血管内皮OFF灵长类动物胚胎干细胞
公开(公告)号：EP1783207A1
公开(公告)日：2007-05-09
申请号：EP05751180.0
申请日：2005-06-15
发明人： NAKAO, Kazuwa , ITOH, Hiroshi , YAMASHITA, Jun , SONE, Masakatsu , YAMAHARA, Kenichi , KONDO, Yasushi , SUZUKI, Yutaka
CPC分类号： C12N5/0691 , A61K35/12 , C12N5/069 , C12N2506/02
摘要： To provide a method for differentiating primate embryonic stem cells into vascular endothelial cells, and a technique using the method. A method for differentiating primate embryonic stem cells into early developmental vascular endothelial cells comprising differentiating primate embryonic stem cells into vascular endothelial cell parker-positive cell population; the early developmental vascular endothelial cells; a method for producing the vascular endothelial cells; a method for amplifying the vascular endothelial cells; a vascular lesion-therapeutic agent containing the early developmental vascular endothelial cells as an active ingredient; a method for revascularization comprising supplying the early developmental vascular endothelial cells; a method for transplantation comprising transplanting the early developmental vascular endothelial cells; and a method for treatment comprising administering the early developmental vascular endothelial cells in a therapeutically effective dose.
摘要翻译： 是提供一种用于鉴别灵长类胚胎干细胞分化成血管内皮细胞的方法，以及使用该方法的技术。 一种用于鉴别灵长类胚胎干细胞分化成早期发育的血管内皮细胞，其包括鉴别灵长类胚胎干细胞分化成血管内皮细胞帕克阳性细胞群的方法; 早期发育血管内皮细胞; 用于制造血管内皮细胞的方法; 用于扩增血管内皮细胞的方法; 血管病变治疗剂含有的早期发育血管内皮细胞作为活性成分的; 血运重建包括提供的早期发育的血管内皮细胞的方法; 移植包括移植的早期发育的血管内皮细胞的方法; 和用于治疗的方法，包括以治疗有效的剂量给药的早期发育血管内皮细胞。
-
4.发明公开ARYLALKYLAMINES AND PROCESS FOR PRODUCTION THEREOF 有权ARYLALKYLAMINE UND VERFAHREN ZU DEREN HERSTELLUNG
公开(公告)号：EP1757582A1
公开(公告)日：2007-02-28
申请号：EP05743307.0
申请日：2005-05-27
发明人： MIYAZAKI, Hiroshi c/o Tanabe Seiyaku Co., Ltd , TSUBAKIMOTO, Junko c/o Tanabe Seiyaku Co., Ltd , YASUDA,Kosuke c/o Tanabe Seiyaku Co., Ltd , TAKAMURO,Iwao c/o Tanabe Seiyaku Co., Ltd , SAKURAI, Osamu c/o Tanabe Seiyaku Co., Ltd , YANAGIDA,Tetsuya, c/o Tanabe Seiyaku Co., Ltd , HISADA,Yutaka c/o Tanabe Seiyaku Co., Ltd
IPC分类号： C07D205/04 , A61K31/397 , A61K31/40 , A61K31/402 , A61K31/4025 , A61K31/404 , A61K31/415 , A61K31/4184 , A61K31/4192 , A61K31/427 , A61K31/4439
CPC分类号： C07D207/14 , C07D205/04 , C07D207/16 , C07D207/27 , C07D207/327 , C07D207/335 , C07D207/34 , C07D211/56 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D403/06 , C07D403/10 , C07D405/12 , C07D409/06 , C07D409/12 , C07D417/04 , C07D417/06 , C07H17/02
摘要： The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensiing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc.
The symbols in the formula represent the following meanings:
Ar: optionally substituted aryl or optionally substituted heteroaryl here, the cyclic portion of the heteroaryl is bicyclic heterocyclic ring in which 5- to 6-membered monocyclic heterocyclic ring containing 1 or 2 hetero atom(s) and benzene ring are fused;
R 1 : a group selected from the group consisting of
optionally substituted cyclic hydrocarbon group, and
optionally substituted heterocyclic group;
n: an integer of 1 to 3;
X: single bonding arm, -CH 2 -, -CO- , - (CH 2 ) m -CO- ,
-CH (R 2 ) -CO-, - (CH 2 ) p -Y-(C(R 3 ) (R 4 )) q -CO-, -NH-CO- or
-N(R 5 ) -CO-;
in the above-mentioned respective definitions of the X, the bonding arm described at the left end represents a bond with R 1 ;
m is an integer of 1 to 3;
p is an integer of 0 to 2;
q is an integer of 0 to 2;
Y: -O- or -SO 2 -;
R 2 : phenyl or lower alkyl;
R 3 , R 4 : each independently represents hydrogen atom or lower alkyl;
R 5 : lower alkyl;
provided that the ring portion of the group represented by R 1 is neither naphthylidine nor partially saturated group thereof, and, when X is -CH 2 - or -CO-, R 1 is not naphthyl.摘要翻译： 本发明涉及由下式[I]表示的芳基烷基胺化合物或其药学上可接受的盐，其制备方法，以及使用上述化合物作为Ca感应剂的活化化合物（CaSR激动剂） 受体，含有上述化合物作为有效成分的药物组合物等。式中的符号表示如下含义：Ar：任选取代的芳基或任选取代的杂芳基，杂芳基的环状部分为双环杂环 含有1或2个杂原子和苯环的5-至6-元单环杂环稠合; R 1：选自任选取代的环状烃基和任选取代的杂环基的基团; n：1〜3的整数; X：单键，-CH 2 - ， - CO - ， - （CH 2）m -CO-，-CH（R 2）-CO-， - （CH 2）p -Y-（C（R 3） （R 4））q -CO - ， - NH-CO-或-N（R 5）-CO-; 在X的上述各自的定义中，左端所示的键合臂表示与R 1的键; m为1〜3的整数。 p为0〜2的整数。 q是0〜2的整数; Y：-O-或-SO 2 - ; R 2：苯基或低级烷基; R 3，R 4各自独立地表示氢原子或低级烷基; R 5：低级烷基; 条件是由R 1表示的基团的环部分既不是萘基也不是部分饱和的基团，并且当X是-CH 2 - 或-CO-时，R 1不是萘基。
-
5.发明公开4- 2- (CYCLOALKYLAMINO) PYRIMIDIN-4-YL ] - (PHENYL) - IMIDAZOLIN-2- ONE DERIVATIVES AS P38 MAP- KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES 有权4- [2-（环烷基）嘧啶-4-基] - （苯基）咪唑啉-2-酮衍生物作为FOR炎性疾病的治疗p38MAP激酶的抑制剂
公开(公告)号：EP1740578A1
公开(公告)日：2007-01-10
申请号：EP05738662.5
申请日：2005-04-28
发明人： KUBO, Akira c/o Tanabe Seiyaku Co. Ltd. , NAKANE, Tetsu c/o Tanabe Seiyaku Co. Ltd. , NAKAJIMA, Tatsuo c/o Tanabe Seiyaku Co. Ltd. , MURAKAMI, Takanori c/o Tanabe Seiyaku Co. Ltd. , MIYOSHI, Hidetaka c/o Tanabe Seiyaku Co. Ltd. , OGASAWARA, Akihito c/o Tanabe Seiyaku Co. Ltd.
IPC分类号： C07D403/14 , C07D417/14 , C07D413/14 , C07D405/14 , C07D409/14 , C07D401/14 , C07D403/04 , A61K31/506 , A61P29/00
CPC分类号： C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要： The present invention is to provide a novel heterocyclic compound of the formula [I]: wherein R1 is a halogen, nitro, an alkyl, etc.; R2 is hydrogen, an alkyl, etc.; Ring A is 2-oxo-4-imidazolin-3,4-diyl, etc.; Ring B is a cycloalkyl, monocyclic saturated heterocyclic group; X is CH, N; Y is a single bond, CO, SO2; Z is O, NH, etc.; and Ring C is an aryl, a heterocyclic group, or a pharmaceutically acceptable salt thereof, which is useful as a p38 MAP kinase inhibitor.
-
公开(公告)号：EP1734974A1
公开(公告)日：2006-12-27
申请号：EP05721429.8
申请日：2005-03-17
发明人： YAMAMURA, Michio, TANABE SEIYAKU CO., LTD. , HAYASHIDA, Koukichi, TANABE SEIYAKU CO., LTD. , TSUCHIDA, Toshito, TANABE SEIYAKU CO., LTD.
IPC分类号： A61K31/7004 , A61P25/24
CPC分类号： A61K31/7004
摘要： An agent for improving depression-like symptoms comprising D-ribose, which may improve and alleviate various symptoms such as hypobulia, general fatigue, sluggishness, enervation, deterioration in concentration, memory impairment, abnormal sensation/obtundation such as impaired sight, decline in thinking power, indefinite complaint, drop in operation efficiency, or feeling of malaise, etc.
-
7.发明公开SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES 审中-公开取代苯并咪唑，苯并三唑和苯并咪唑酮-O葡萄糖苷
公开(公告)号：EP1679966A2
公开(公告)日：2006-07-19
申请号：EP04779671.9
申请日：2004-07-30
发明人： URBANSKI, Maud
CPC分类号： C07H15/26
摘要： This invention relates to to substituted benzimidazole-O-glucosides, benztriazole-O-glucosides, and benzimidazolone-O-glucosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X.
-
公开(公告)号：EP1679965A2
公开(公告)日：2006-07-19
申请号：EP04779628.9
申请日：2004-07-30
CPC分类号： C07H7/06 , Y10S514/866 , Y10S514/909
摘要： This invention relates to substituted fused heterocyclic C-glycosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X.
-
公开(公告)号：EP1539696A2
公开(公告)日：2005-06-15
申请号：EP03784602.9
申请日：2003-08-08
发明人： WITHERINGTON, Jason,c/o GlaxoSmithKline p.l.c. , ELLIOTT, Richard L.,c/o GlaxoSmithKline p.l.c.
IPC分类号： C07D213/00
CPC分类号： C07D213/64 , C07D211/76 , C07D401/12
摘要： The present invention relates to novel pyridone derivatives capable of inhibiting a4 integrin medicated cell adhesion, processes for their preparation, compositions comprising them and their use in the treatment of diseases capable of being modulated by the inhibition of cell adhesion.
-
10.发明公开PROCESS FOR THE PRODUCTION OF MICROSPHERES AND UNIT THEREFOR 审中-公开VERFAHREN ZUR HERSTELLUNG VONMIKROKÜGELCHENUNDGERÄTDAFÜR
公开(公告)号：EP1537846A1
公开(公告)日：2005-06-08
申请号：EP03795361.9
申请日：2003-09-10
IPC分类号： A61J3/02
CPC分类号： B01J13/04 , A61K9/1647 , A61K9/1694 , A61K9/19
摘要： In the method for preparation of microspheres by in-water drying method, an iterative process is employed, which comprises emulsifying a medicament-containing polymer solution (4) containing an organic solvent in an emulsifying device (1) to form an emulsion; transferring this emulsion into a microsphere storage tank (2); introducing a part of said emulsion to a cross flow filter (3) from the microsphere storage tank; and returning a liquid passing over the cross flow filter to the microsphere storage tank (2). Since a small amount of microsphere is repeatedly produced, this process permits the downsizing and airtight closing of an apparatus therefor, and further makes it possible to freely control the production scale of microsphere.
摘要翻译： 在通过水中干燥法制备微球的方法中，采用迭代方法，其包括在乳化装置（1）中乳化含有有机溶剂的含药聚合物溶液（4）以形成乳液; 将该乳液转移到微球储存罐（2）中; 将一部分所述乳液从微球储存罐引入交叉流过滤器（3）; 并将通过所述交叉流过滤器的液体返回到所述微球储存罐（2）。 由于反复产生少量的微球，所以该方法允许其装置的小型化和气密封闭，并且还可以自由地控制微球的生产规模。
-
-
-
-
-
-
-
-
-
搜索结果
610 条记录 (耗时 0.036 秒)
